{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T23:14:41Z","timestamp":1783379681043,"version":"3.54.6"},"reference-count":30,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003790","name":"Hiroshima University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003790","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.urolonc.2026.05.012","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T07:08:19Z","timestamp":1780643299000},"page":"108-119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nectin-4 drives aggressive tumor biology and poor prognosis in renal cell carcinoma"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1953-3240","authenticated-orcid":false,"given":"Tomoya","family":"Hatayama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1525-5463","authenticated-orcid":false,"given":"Yohei","family":"Sekino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Babasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Sentani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikaru","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Shikuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyosuke","family":"Iwane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Yukihiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kohada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Kobatake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Kitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Hieda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Hinoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Hinata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.urolonc.2026.05.012_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.urolonc.2026.05.012_bib0002","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.eururo.2022.06.016","article-title":"The 2022 World Health Organization Classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours","volume":"82","author":"Moch","year":"2022","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.05.012_bib0003","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.eururo.2018.10.010","article-title":"Systemic treatment of metastatic clear cell renal cell carcinoma in 2018: current paradigms, use of immunotherapy, and future directions","volume":"75","author":"Lalani","year":"2019","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.05.012_bib0004","first-page":"507","article-title":"Treatment of renal cell carcinoma: current status and future directions","volume":"67","author":"Barata","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.urolonc.2026.05.012_bib0005","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/JU.0000000000001911","article-title":"Renal mass and localized Renal cancer: evaluation, management, and follow-up: AUA guideline: part I","volume":"206","author":"Campbell","year":"2021","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.05.012_bib0006","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMra1601333","article-title":"Systemic therapy for metastatic renal-cell carcinoma","volume":"376","author":"Choueiri","year":"2017","journal-title":"N Engl J Med"},{"issue":"46","key":"10.1016\/j.urolonc.2026.05.012_bib0007","doi-asserted-by":"crossref","first-page":"43205","DOI":"10.1074\/jbc.M103810200","article-title":"Nectin4\/PRR4, a new afadin-associated member of the nectin family that trans-interacts with nectin1\/PRR1 through V domain interaction","volume":"276","author":"Reymond","year":"2001","journal-title":"J Biol Chem"},{"issue":"8","key":"10.1016\/j.urolonc.2026.05.012_bib0008","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1349-7006.2003.tb01499.x","article-title":"Nectins and nectin-like molecules: roles in cell adhesion, migration, and polarization","volume":"94","author":"Takai","year":"2003","journal-title":"Cancer Sci"},{"issue":"10","key":"10.1016\/j.urolonc.2026.05.012_bib0009","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab Vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2026.05.012_bib0010","article-title":"Nectin-4 expression in upper and lower tract urothelial carcinoma: correlation with early-stage disease and prognostic relevance","author":"Kobayashi","year":"2025","journal-title":"Virchows Arch"},{"issue":"10","key":"10.1016\/j.urolonc.2026.05.012_bib0011","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Tumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.urolonc.2026.05.012_bib0012","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13046-015-0144-7","article-title":"Nectin-4 expression contributes to tumor proliferation, angiogenesis and patient prognosis in human pancreatic cancer","volume":"34","author":"Nishiwada","year":"2015","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.urolonc.2026.05.012_bib0013","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/annonc\/mdw678","article-title":"Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer","volume":"28","author":"Rabet","year":"2017","journal-title":"Ann Oncol"},{"issue":"16","key":"10.1016\/j.urolonc.2026.05.012_bib0014","doi-asserted-by":"crossref","first-page":"6694","DOI":"10.1158\/0008-5472.CAN-09-0016","article-title":"Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer","volume":"69","author":"Takano","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2026.05.012_bib0015","series-title":"TNM classification of malignant tumours","author":"Brierley","year":"2017"},{"key":"10.1016\/j.urolonc.2026.05.012_bib0016","article-title":"al contribution of BACH1 to bladder cancer progression via upregulating epithelial-mesenchymal transition pathway","author":"Hatayama","year":"2025","journal-title":"Cancer Sci"},{"issue":"2","key":"10.1016\/j.urolonc.2026.05.012_bib0017","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/cas.15607","article-title":"BACH1 promotes clear cell renal cell carcinoma progression by upregulating oxidative stress-related tumorigenicity","volume":"114","author":"Takemoto","year":"2023","journal-title":"Cancer Sci"},{"issue":"5","key":"10.1016\/j.urolonc.2026.05.012_bib0018","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70710","article-title":"DGKalpha enhances tumorigenic activity in bladder cancer patients with chronic kidney disease","volume":"14","author":"Takemoto","year":"2025","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.urolonc.2026.05.012_bib0019","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-22561-7","article-title":"KDM6A deficiency promotes tumor progression and resistance to cabozantinib treatment in clear cell renal cell carcinoma","volume":"15","author":"Kohada","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.urolonc.2026.05.012_bib0020","doi-asserted-by":"crossref","DOI":"10.1038\/s41440-025-02535-y","article-title":"Angiotensin II type 1 receptor signaling promotes bladder cancer progression and its inhibition by Losartan","author":"Yamanaka","year":"2026","journal-title":"Hypertens Res"},{"issue":"269","key":"10.1016\/j.urolonc.2026.05.012_bib0021","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"issue":"2","key":"10.1016\/j.urolonc.2026.05.012_bib0022","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/s43018-024-00896-w","article-title":"Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma","volume":"6","author":"Jammihal","year":"2025","journal-title":"Nat Cancer"},{"issue":"6","key":"10.1016\/j.urolonc.2026.05.012_bib0023","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/s41591-020-0839-y","article-title":"Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma","volume":"26","author":"Braun","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.urolonc.2026.05.012_bib0024","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.biocel.2017.06.007","article-title":"Nectin-4 is a breast cancer stem cell marker that induces WNT\/beta-catenin signaling via Pi3k\/akt axis","volume":"89","author":"Siddharth","year":"2017","journal-title":"Int J Biochem Cell Biol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.05.012_bib0025","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.canlet.2016.02.049","article-title":"A novel PI3K\/AKT signaling axis mediates Nectin-4-induced gallbladder cancer cell proliferation, metastasis and tumor growth","volume":"375","author":"Zhang","year":"2016","journal-title":"Cancer Lett"},{"key":"10.1016\/j.urolonc.2026.05.012_bib0026","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.humpath.2017.10.034","article-title":"Nectin-4 promotes gastric cancer progression via the PI3K\/AKT signaling pathway","volume":"72","author":"Zhang","year":"2018","journal-title":"Hum Pathol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.05.012_bib0027","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/s41467-021-21068-9","article-title":"Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma","volume":"12","author":"Bakouny","year":"2021","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.urolonc.2026.05.012_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100101","article-title":"Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial","volume":"6","author":"Choueiri","year":"2021","journal-title":"ESMO Open"},{"issue":"12","key":"10.1016\/j.urolonc.2026.05.012_bib0029","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1158\/2326-6066.CIR-15-0150","article-title":"PD-1 and PD-L1 expression in renal cell carcinoma with sarcomatoid differentiation","volume":"3","author":"Joseph","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"11","key":"10.1016\/j.urolonc.2026.05.012_bib0030","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1016\/j.ccell.2025.07.010","article-title":"Comprehensive tumor-immune profiling reveals mediators of paradoxical immune sensitivity in sarcomatoid renal cell carcinoma","volume":"43","author":"Salgia","year":"2025","journal-title":"Cancer Cell"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926005314?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926005314?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T22:28:07Z","timestamp":1783376887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926005314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1078143926005314"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.05.012","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nectin-4 drives aggressive tumor biology and poor prognosis in renal cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}